Tracking the evolution of non-headache symptoms through the migraine attack
ConclusionMigraine is a complex neurological disorder with a wide constellation of non-headache symptoms that can affect the burden of the disease. A better characterization of the evolution of non-headache symptoms through the different phases of migraine can enrich our knowledge on migraine pathophysiology and improve the management of the disease. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 23, 2022 Category: Neurology Source Type: research
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure
ConclusionA standardized definition of recurrence is necessary to help physicians evaluate recurrence rates of different abortive agents for migraine. Sustained pain relief or freedom may be more comprehensive efficacy outcome measures than recurrence. Future efficacy studies should be encouraged to use the recommended definition of sustained pain freedom set by the International Headache Society. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 22, 2022 Category: Neurology Source Type: research
Genome-wide analyses identify novel risk loci for cluster headache in Han Chinese residing in Taiwan
ConclusionsThis study revealed the genetic architecture and novel susceptible loci of cluster headache in Han Chinese residing in Taiwan. Our findings support the common genetic contributions of cluster headache across ethnicities and provide novel mechanistic insights into the pathogenesis of cluster headache. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 21, 2022 Category: Neurology Source Type: research
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
ConclusionDRAGON study demonstrated the efficacy and safety of erenumab 70 mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials.Trial registrationNCT03867201 (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 21, 2022 Category: Neurology Source Type: research
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients
ConclusionMicrovascular decompression is an effective treatment for classical and idiopathic (only patients with a neurovascular contact) trigeminal neuralgia with a high chance of a long-lasting effect. The chance of an excellent outcome was highest in men and in patients with classical trigeminal neuralgia. Complications are relatively frequent warranting thorough patient evaluation and information preoperatively.Trial registrationClinical.trials.gov registration no.NCT04445766. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 19, 2022 Category: Neurology Source Type: research
Comment regarding: what is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta ‑analysis of clinical trials
AbstractIn Woldeamanuel and Oliveira (2022) ’s article about the efficacy of exercise in the treatment of migraine, the ranking of the efficacy of strength training (mean difference, − 3.55), aerobic exercise (mean difference, − 2.18 to − 3.13), topiramate (mean difference, − 0.98), and amitriptyline (mean difference, 3.82) using network meta-analysis can mislead readers. First, the inclusion criteria were reported at a monthly frequency of migraine and the end of the intervention, but some article did not meet the inclusion criteria or had data inconsistency. Second, there was an inconsistency in the pla...
Source: The Journal of Headache and Pain - November 18, 2022 Category: Neurology Source Type: research
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
ConclusionsOverall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced.Trial registrationBASEC ID 2018 –02,375 in the Register of All Projects in Switzerland (RAPS).Graphical Abstract (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 18, 2022 Category: Neurology Source Type: research
Enhanced pain facilitation rather than impaired pain inhibition in burning mouth syndrome female patients
ConclusionThis study reveals that there is no impairment of endogenous pain inhibition mechanisms in BMS patients, but rather an increase in pain facilitation. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 18, 2022 Category: Neurology Source Type: research
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study
ConclusionsThis post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy.Trial registrationClinicalTrials.govNCT03828539. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 15, 2022 Category: Neurology Source Type: research
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency
ConclusionsThe substantial between-study heterogeneity demands cautious interpretation of our estimates. Studies showed wide methodological variations, and many lacked rigor. Overall, the evidence was insufficient to support reliable prevalence estimation or characterization of premonitory symptoms. More data are needed, of better quality, to confirm the existence of a distinctive premonitory phase of migraine, and its features. Methodological guidelines based on expert consensus are a prerequisite. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 12, 2022 Category: Neurology Source Type: research
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
ConclusionsLong-term sustained effectiveness of erenumab was reported only by a minority of resistant CM patients. Although more research in resistant migraine is needed, Erenumab can provide long-term meaningful reduction in migraine load and migraine-related disability in some patients. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 4, 2022 Category: Neurology Source Type: research
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
ConclusionsA critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds targeting specific molecular mechanisms. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - November 1, 2022 Category: Neurology Source Type: research
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China
ConclusionsIn contrast to Western countries, SUNCT and SUNA in China have a greater female predominance and an earlier onset. The shared core phenotype of SUNCT and SUNA, despite their partial differences, suggests that they are the same clinical entity. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - October 26, 2022 Category: Neurology Source Type: research
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation
ConclusionCardiac cephalalgia characteristics are variable and the headache features described in the diagnostic criterion C3 might not be adequate. Given that cardiac cephalalgia can be the manifestation of a life-threatening condition it is important to increase the knowledge about this entity. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - October 20, 2022 Category: Neurology Source Type: research
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
ConclusionIntravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - October 17, 2022 Category: Neurology Source Type: research
